연골 무형성증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Achondroplasia Insights and Trends

• According to DelveInsight's analysis, the Achondroplasia market size was found to be ~USD 600 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Achondroplasia is typically identifiable early in life due to its distinct clinical and radiographic features; however, variability in presentation and gaps in awareness can lead to delays in diagnosis and referral. This underscores the importance of early genetic confirmation, longitudinal growth monitoring, and proactive management to mitigate complications and improve long-term outcomes.
• Disease management in achondroplasia remains centered on multidisciplinary care, including regular monitoring of skeletal and neurological complications, alongside supportive interventions such as physical therapy and surgical procedures when required, to optimize functional outcomes and quality of life.
• The achondroplasia treatment paradigm is shifting from supportive care toward targeted, disease-modifying therapies that address underlying FGFR3 pathway dysregulation. This evolution is driven by improved disease understanding and the availability of novel agents such as Vosoritide (VOXZOGO) and Navepegritide; TransCon CNP (YUVIWEL).
• The current achondroplasia treatment landscape includes a broad range of marketed targeted therapies spanning multiple mechanisms of action, developed by leading pharmaceutical companies, including Ascendis Pharma (YUVIWEL) and BioMarin Pharmaceutical (VOXZOGO), reflecting continued innovation and competition in the JIA therapeutic space.
• Whereas the emerging achondroplasia pipeline continues to expand with mid- and late-stage assets such as QED Therapeutics (BridgeBio)/Novartis/Kyowa Kirin (BBP-831/BGJ398), RIBOMIC (RBM-007), and BioMarin Pharmaceutical (BMN 333) are being evaluated.

DelveInsight's 'Achondroplasia - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of Achondroplasia, historical and forecasted epidemiology, as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Achondroplasia market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Achondroplasia patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Achondroplasia and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Achondroplasia Market

Rising Achondroplasia Prevalence

The slightly increasing prevalence of Achondroplasia, particularly among males, is a primary driver of the Achondroplasia market expansion. In the US, in 2025, there were ~ 14,500 diagnosed prevalent cases of Achondroplasia.

Rising Opportunities in Targeted Therapies

Emerging evidence supporting the efficacy and safety of novel targeted therapies over traditional symptomatic management highlights a growing opportunity for drug developers to focus on approaches that directly address the underlying genetic cause, improve bone growth outcomes, and ensure long-term functional benefits and quality of life in patients with achondroplasia.

Emerging Achondroplasia Competitive Landscape

Emerging achondroplasia drugs in clinical trials, such as infigratinib (BBP-831/BGJ398), RBM-007 (umedaptanib pegol), BMN 333, and others, are fueling market growth by addressing unmet needs in this rare skeletal dysplasia.

Achondroplasia Understanding and Treatment Algorithm

Achondroplasia Overview

Achondroplasia is the most common form of disproportionate short stature, caused by a genetic mutation that affects bone growth and development, particularly in the long bones. It typically presents at birth and is characterized by shortened limbs, a relatively normal trunk, and distinctive facial features. While intelligence and life expectancy are generally normal, individuals may experience complications such as spinal stenosis, respiratory issues, and joint problems, especially in more severe cases. Achondroplasia is primarily caused by mutations in the FGFR3 gene that limit cartilage conversion to bone.

Achondroplasia Diagnosis

Achondroplasia is diagnosed through clinical evaluation and genetic testing, often identified at birth or during prenatal screening. Physical features such as disproportionate short stature, enlarged head, and characteristic facial features raise suspicion. Imaging (X-rays) supports the diagnosis by showing typical skeletal changes, while genetic testing confirms mutations in the FGFR3 gene.

Achondroplasia Treatment

The primary goals of Achondroplasia management are to optimize linear growth, prevent and manage complications, improve functional outcomes, and support overall quality of life and psychosocial development. Care is multidisciplinary, involving pediatricians, geneticists, orthopedic surgeons, and neurologists, with regular monitoring for complications such as spinal stenosis, foramen magnum compression, and obstructive sleep apnea. Management includes supportive measures such as physical therapy and, when required, surgical interventions to address skeletal and neurological issues. Pharmacologic therapy has evolved with targeted treatments such as VOXZOGO and YUVIWEL, which act on the underlying FGFR3 pathway to promote endochondral bone growth, marking a shift toward disease-modifying approaches beyond symptomatic care.

Achondroplasia Unmet Needs

The section "unmet needs of Achondroplasia" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited disease-modifying therapies, with most treatments focused on symptom management

2. High lifelong burden due to multiple comorbidities and complications

3. Restricted access and high cost of emerging therapies

4. Gaps in early diagnosis and optimal intervention timing, and others...

Comprehensive unmet needs insights in Achondroplasia and their strategic implications are provided in the full report.

Achondroplasia Epidemiology

Key Findings from Achondroplasia Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalent cases of Achondroplasia in the 7MM were approximately 28,500 in 2025, with the US accounting for the highest share.
• Among the EU4, France accounted for the highest number of diagnosed prevalent cases of Achondroplasia, followed by Germany, whereas Spain accounted for the lowest number of cases in 2025.
• The observed slight male predominance and earlier onset of Achondroplasia highlight the importance of early diagnosis, timely clinical intervention, and continuous monitoring to manage complications effectively.

Achondroplasia Drug Chapters & Competitive Analysis

The Achondroplasia drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Achondroplasia treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Achondroplasia therapeutics market.

Approved Therapies for Achondroplasia

Navepegritide; TransCon CNP (YUVIWEL): Ascendis Pharma

YUVIWEL, developed by Ascendis Pharma, is a long-acting prodrug of C-type natriuretic peptide (CNP) designed to address the underlying cause of achondroplasia. It works by counteracting the overactive FGFR3 signaling pathway, which normally inhibits bone growth, thereby restoring balance in growth plate activity. Using TransCon technology, it provides sustained release of active CNP, enabling continuous stimulation of chondrocyte proliferation and differentiation, ultimately promoting more normalized endochondral bone growth.

Achondroplasia Pipeline Analysis

Infigratinib (BBP-831/BGJ398): QED Therapeutics (BridgeBio)/Novartis/Kyowa Kirin

Infigratinib, developed by QED Therapeutics in collaboration with Novartis and Kyowa Kirin, is an oral, selective FGFR1-3 tyrosine kinase inhibitor designed to target the underlying genetic driver of Achondroplasia. It works by directly inhibiting the overactive FGFR3 signaling pathway responsible for impaired bone growth, thereby restoring downstream signaling balance in growth plate chondrocytes. This targeted mechanism aims to normalize endochondral ossification and promote skeletal growth, offering a precision-based approach that addresses the root cause of the disorder.

Achondroplasia Key Players, Market Leaders, and Emerging Companies

• Ascendis Pharma
• BioMarin Pharmaceutical
• QED Therapeutics (BridgeBio)
• Novartis
• Kyowa Kirin
• RIBOMIC, and others

Achondroplasia Drug Updates

• In March 2026, RIBOMIC announced the summary report on the Phase II clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in paediatric patients with achondroplasia.
• In March 2026, RIBOMIC submitted an IND application for a Phase III clinical trial in Japan to the Pharmaceuticals and Medical Devices Agency (PMDA), the regulatory authority, for umedaptanib pegol (antiFGF2 aptamer) in pediatric patients (ages 2 to 14) with achondroplasia.
• In February 2026, BridgeBio Pharma announced positive topline results from the global Phase III (PROPEL 3) study of oral infigratinib in children with achondroplasia, successfully meeting the primary endpoint of change in annualized height velocity (AHV) at Week 52 (p<0.0001).
• In August 2025, the company reported Phase I data showing that BMN 333 achieved over threefold higher AUC pharmacokinetic levels than other long-acting CNPs, with no safety concerns observed.

Drug Class Insights

Achondroplasia Market Outlook

The Achondroplasia market is undergoing a significant transformation, shifting from a historically supportive care-focused approach toward targeted, disease-modifying therapies that address the underlying FGFR3-driven pathology. The approval and uptake of CNP analogs such as VOXZOGO (vosoritide) have established the first wave of mechanism-based treatment, while next-generation agents like TransCon CNP (navepegritide) aim to improve convenience and sustained efficacy through prolonged exposure. Additionally, emerging therapies such as Infigratinib highlight a growing focus on directly modulating FGFR3 signaling, further diversifying the therapeutic landscape.

With the continued advancement of late-stage pipeline candidates, including long-acting CNP formulations and oral FGFR inhibitors, the achondroplasia treatment landscape is becoming increasingly competitive and innovation-driven, aligning with broader trends in rare genetic disorders. The United States represents the largest market, driven by higher diagnosis rates, strong access to specialty care, favorable reimbursement frameworks, and increasing awareness among clinicians and caregivers, followed by Europe and Japan. Improved genetic testing and early diagnosis are also contributing to greater treatment uptake.

Overall, the introduction of differentiated disease-modifying therapies, expansion of pipeline assets with novel mechanisms, improving diagnostic capabilities, and growing awareness of long-term disease burden are expected to drive steady growth in the 7MM achondroplasia market from 2022 to 2036, creating significant commercial opportunities for both marketed therapies and emerging pipeline candidates.

• In 2025, the 7MM achondroplasia market reached an estimated USD 600 million, led by the United States, which dominated with the largest share.
• The Achondroplasia market is evolving as the treatment paradigm shifts from supportive and symptomatic management toward targeted disease-modifying therapies, with CNP analogs such as vosoritide and long-acting formulations like navepegritide (TransCon CNP) gaining traction due to their ability to address the underlying FGFR3 pathway dysregulation and promote more normalized bone growth.
• Regional market dynamics indicate that the United States leads in revenue generation, while Europe and Japan are witnessing steady growth, driven by improved diagnosis rates, increasing awareness of genetic disorders, and expanding access to novel targeted therapies that focus on long-term disease modification rather than symptomatic relief.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Achondroplasia (2022-2036 Forecast)

The Achondroplasia market comprises targeted growth-modifying therapies, emerging next-generation CNP analogs, and multidisciplinary non-drug management approaches, each addressing different aspects of impaired bone growth, skeletal complications, and patient quality of life.

• Targeted growth-modifying therapies: Agents such as VOXZOGO act as C-type natriuretic peptide (CNP) analogs, directly targeting the overactive FGFR3 signaling pathway to promote endochondral bone growth. These therapies represent the first disease-modifying approach but require long-term administration and early initiation for optimal outcomes.
• Emerging next-generation CNP analogs: Novel long-acting therapies such as navepegritide are being developed to provide sustained exposure and improved convenience (e.g., weekly dosing), aiming to enhance efficacy, adherence, and overall growth outcomes compared to earlier agents.

Targeted CNP-based therapies define the core innovation landscape in achondroplasia, shifting the paradigm from symptomatic and surgical management toward disease-modifying approaches, while next-generation long-acting agents and holistic care strategies are expected to drive future advancements.

Achondroplasia Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Achondroplasia market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in achondroplasia is expected to vary across CNP analogs, emerging long-acting peptide therapies, and supportive management approaches. Recently approved and emerging targeted therapies such as VOXZOGO and YUVIWEL are anticipated to demonstrate gradual to moderate uptake, supported by their disease-modifying mechanisms targeting the underlying FGFR3 pathway, defined pediatric patient populations, and increasing physician awareness. Their adoption is likely to be driven by the lack of curative options, limitations of traditional supportive care, and the need to improve long-term growth outcomes and quality of life.

In comparison, other emerging therapies targeting alternative pathways or gene-based approaches are expected to witness slower but progressive uptake as long-term safety and efficacy data mature and clinical experience expands in managing this rare genetic disorder.

Market Access and Reimbursement of Achondroplasia

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Further details are provided in the final report....

Achondroplasia Therapies Price Scenario & Trends

Pricing and analogue assessment of Achondroplasia therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Achondroplasia

To keep up with Achondroplasia market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Achondroplasia emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Achondroplasia, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, University of Nottingham, and Japanese Red Cross Central Blood Institute, etc. were contacted. Their opinion helps understand and validate current and emerging Achondroplasia therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Achondroplasia.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Achondroplasia, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Achondroplasia, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Achondroplasia market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Achondroplasia market.

Report Insights

• Achondroplasia Patient Population Forecast
• Achondroplasia Therapeutics Market Size
• Achondroplasia Pipeline Analysis
• Achondroplasia Market Size and Trends
• Achondroplasia Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Achondroplasia Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Achondroplasia Treatment Addressable Market (TAM)
• Achondroplasia Competitive Landscape
• Achondroplasia Major Companies Insights
• Achondroplasia Price Trends and Analogue Assessment
• Achondroplasia Therapies Drug Adoption/Uptake
• Achondroplasia Therapies Peak Patient Share analysis

Report Assessment

• Achondroplasia Current Treatment Practices
• Achondroplasia Unmet Needs
• Achondroplasia Clinical Development Analysis
• Achondroplasia Emerging Drugs Product Profiles
• Achondroplasia Market Attractiveness
• Achondroplasia Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Achondroplasia market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Achondroplasia?
• What are the disease risks, burdens, and unmet needs of Achondroplasia? What will be the growth opportunities across the 7MM concerning the patient population with Achondroplasia?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Achondroplasia? What are the current guidelines for treating Achondroplasia in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Achondroplasia market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology of Achondroplasia

6. Achondroplasia Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (by Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of Achondroplasia by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of Achondroplasia by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Achondroplasia

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Causes
• 7.4. Risk factors
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm

8. Treatment

• 8.1. Algorithm for the Treatment of Achondroplasia
• 8.2. Guidelines for the Treatment of Achondroplasia

9. Epidemiology and Patient Population of Achondroplasia

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Diagnosed Prevalent Cases of Achondroplasia in the 7MM
• 9.4. The United States
  • 9.4.1. Total Diagnosed Prevalent Cases of Achondroplasia in the US
  • 9.4.2. Gender-Specific Diagnosed Prevalent Cases of Achondroplasia in the US
  • 9.4.3. Total treated Cases of Achondroplasia in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Achondroplasia in EU4 and the UK
  • 9.5.2. Gender-Specific Diagnosed Prevalent Cases of Achondroplasia in EU4 and the UK
  • 9.5.3. Total treated Cases of Achondroplasia in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Achondroplasia in Japan
  • 9.6.2. Gender-Specific Diagnosed Prevalent Cases of Achondroplasia in Japan
  • 9.6.3. Total treated Cases of Achondroplasia in Japan

10. Patient Journey of Achondroplasia

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Achondroplasia
• 11.2. Navepegritide; TransCon CNP (YUVIWEL): Ascendis Pharma
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. Vosoritide (VOXZOGO): BioMarin Pharmaceutical
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Achondroplasia
• 12.2. Infigratinib (BBP-831/BGJ398): QED Therapeutics (BridgeBio)/Novartis/Kyowa Kirin
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views
• 12.3. RBM-007 (umedaptanib pegol): RIBOMIC
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst's Views

13. Achondroplasia: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Achondroplasia
• 13.3. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
  • 13.3.2. Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptakes
• 13.4. Conjoint Analysis of Achondroplasia
• 13.5. Total Market Size of Achondroplasia in the 7MM
• 13.6. Total Market Size of Achondroplasia by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of Achondroplasia in the United States
  • 13.7.2. Total Market Size of Achondroplasia by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of Achondroplasia in EU4 and the UK
  • 13.8.2. Total Market Size of Achondroplasia by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of Achondroplasia in Japan
  • 13.9.2. Total Market Size of Achondroplasia by Therapies in Japan

14. Unmet Needs of Achondroplasia

15. SWOT Analysis of Achondroplasia

16. KOL Views of Achondroplasia

17. Market Access and Reimbursement of Achondroplasia

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Achondroplasia Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight